The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse Clinical Trial

Official title:

Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00498667
• Other study ID #: cc-NHL2615_CTIL
• Status: Withdrawn
• Phase: N/A
• First received: July 8, 2007
• Last updated: May 5, 2015
• Start date: December 2006
• Est. completion date: December 2014

Study information

• Verified date: May 2015
• Source: Rambam Health Care Campus
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Observational

Clinical Trial Summary

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Description:

Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2014
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• aggressive non-Hodgkin lymphoma b cells

• age 18-70

• bilirubin less then 2

• creatinine less then 2

• Pet/CT performed post 2 cycles

Exclusion Criteria:

• no PET/CT post 2 cycles performed

• bilirubin >2

• creatinine more then 2

• HIV positivity

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Non-Hodgkin
• Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Locations

Country	Name	City	State
Israel	RAMBAM health care Campus	Haifa

Sponsors (1)

Lead Sponsor	Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression free survival		5 years	No